On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we’ll share results of the SWOGS1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then, we'll hear about a study which aimed to evaluate whether personalized ctDNA profiling could aid in identifying recurrence in patients with soft-tissue sarcomas.

To listen to more podcasts from ASCO, visit asco.org/podcasts.